Explore the words cloud of the HIT-CF project. It provides you a very rough idea of what is the project "HIT-CF" about.
The following table provides information about the project.
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
|Coordinator Country||Netherlands [NL]|
|Total cost||8˙753˙615 €|
|EC max contribution||6˙701˙365 € (77%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2018-01-01 to 2022-12-31|
Take a look of project's partnership.
|1||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||coordinator||1˙434˙417.00|
|2||JULIUS CLINICAL RESEARCH BV||NL (ZEIST)||participant||2˙703˙152.00|
|3||STICHTING HUBRECHT ORGANOID TECHNOLOGY||NL (UTRECHT)||participant||1˙088˙050.00|
|4||KATHOLIEKE UNIVERSITEIT LEUVEN||BE (LEUVEN)||participant||386˙250.00|
|5||EUROPEAN CYSTIC FIBROSIS SOCIETY||DK (KARUP)||participant||334˙740.00|
|6||PATERGRUS BVBA||BE (AALTER)||participant||302˙075.00|
|7||FCIENCIAS.ID - ASSOCIACAO PARA A INVESTIGACAO E DESENVOLVIMENTO DE CIENCIAS||PT (LISBON)||participant||257˙367.00|
|8||CYSTIC FIBROSIS EUROPE EV||DE (BONN)||participant||141˙312.00|
|9||FLATLEY DISCOVERY LAB LLC||US (CANTON, MASSACHUSETTS)||participant||27˙000.00|
In our HIT-CF project, we aim to bring personalised disease modifying therapies to cystic fibrosis (CF) patients with ultra-rare CFTR mutations, who could otherwise never get access to such treatment. Once we have proven our unique concept, the CF community can easily extend our state-of-the-art methodology to all CF patients such that HIT-CF will impact the entire CF field.
We will achieve our goals by means of a randomised, double-blind, placebo-controlled, repeated-crossover, three-armed platform trial with prospectively defined meta-analysis to evaluate efficacy at group and individual level. HIT-CF is designed to enable access to the most relevant global drug products, and each trial arm will test a drug product candidate (a single compound or a compound combination) from one of our pharmaceutical consortium partners. The patients will be assigned to the specific trial based on the effect of the drug product candidates on cultured intestinal miniature organs (termed organoids) grown from rectal biopsies, instead of based on typical genotyping only. In parallel with this H2020 project, our pharmaceutical partners will obtain market approval of their drug product candidates for common (F508del or gating) mutations in the CFTR gene. Ultimately, our project will enable ‘managed’ off-label access to these therapies towards patient groups or individuals who show response to the therapy in a prospective intestinal organoid test.
One of the major impacts of this project will be the innovative methodologies to acquire reimbursement for current and future off-label treatments of people with CFTR mutations. This will represent a real paradigm shift in CF treatment as it implements a new type of personalized medicine paradigm based on organoids, by shifting therapeutic trials from patients to the laboratory.
|A suite of branded template material and a website||Other||2019-11-08 11:12:33|
Take a look to the deliverables list in detail: detailed list of HIT-CF deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HIT-CF" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HIT-CF" are provided by the European Opendata Portal: CORDIS opendata.
Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Latin American multidisciplinary networkRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
Palliative care in Parkinson’s diseaseRead More